Intracoronary Pressure Gradient Measurement in Acute Myocardial Infarction Patients with the No-Reflow Phenomenon during Primary Percutaneous Coronary Intervention
The no-reflow phenomenon is a critical complication observed in patients undergoing primary percutaneous coronary intervention (pPCI) for acute myocardial infarction (AMI). This phenomenon is characterized by the absence of myocardial reperfusion despite successful opening of the infarct-related artery (IRA). The underlying mechanisms of no-reflow are complex and multifactorial, involving microvascular obstruction, endothelial dysfunction, platelet aggregation, and inflammation. Despite extensive research, the pathogenesis and optimal treatment strategies for no-reflow remain incompletely understood. This study aimed to investigate the intracoronary pressure gradient in patients experiencing no-reflow during emergent pPCI and explore the potential mechanisms and therapeutic implications of this phenomenon.
The study was conducted at the Department of Coronary Care Unit, Tianjin Chest Hospital, China, from September 1st, 2018, to June 30th, 2019. Patients presenting with ST-segment elevation myocardial infarction (STEMI) within 12 hours of symptom onset and undergoing successful coronary stent implantation were included. Exclusion criteria included significant cardiac insufficiency (left ventricular ejection fraction <40%), ostial lesions, and extremely tortuous or bifurcated coronary arteries. A total of 59 patients were enrolled, with 33 assigned to the no-reflow group (TIMI flow grade 0-1) and 26 to the control group (TIMI flow grade 3).
Intracoronary pressure measurements were performed using an aspiration catheter, which was advanced to the distal segment of the culprit artery. Pressure readings were recorded continuously as the catheter was pulled back from the distal to the proximal segment. At least 12 cardiac cycles were recorded for each patient. The forward systolic pressure gradient was calculated as the difference between proximal systolic pressure and distal systolic pressure, while the forward diastolic pressure gradient was the difference between proximal diastolic pressure and distal diastolic pressure. Statistical comparisons between groups were made using the Student t-test, Mann-Whitney U-test, or Chi-square test, as appropriate.
The results revealed significant differences in intracoronary pressure gradients between the no-reflow and control groups. The forward systolic pressure gradient was -1.3 mmHg (interquartile range: -4.8 to 0.7) in the no-reflow group and 3.8 mmHg (interquartile range: 0.8 to 8.8) in the control group (Z = -3.989, P < 0.001). Similarly, the forward diastolic pressure gradient was -1.0 mmHg (interquartile range: -3.2 to 0) in the no-reflow group and 4.6 mmHg (interquartile range: 0 to 16.5) in the control group (Z = -3.851, P < 0.001). These findings indicate that no-reflow is associated with an inverse pressure gradient, where distal pressures are higher than proximal pressures, limiting antegrade blood flow.
To further explore the therapeutic potential of vasodilators in no-reflow, intracoronary administration of nicorandil was evaluated. Nicorandil was administered as a bolus injection (2-6 mg) through the aspiration catheter into the distal coronary artery. Repeated injections were allowed until TIMI grade 3 flow was achieved. The intracoronary pressure gradients were measured before and after nicorandil administration. Significant improvements were observed in both systolic and diastolic pressure gradients following nicorandil treatment (Z = -3.668, P < 0.001 for systolic gradient; Z = -3.530, P < 0.001 for diastolic gradient). These results suggest that distal administration of nicorandil can restore normal coronary pressure gradients and improve microcirculatory function.
The study also highlighted the importance of local hemodynamic abnormalities in the development of no-reflow. The inverse pressure gradient observed in no-reflow arteries is consistent with findings from Doppler guidewire studies, which have shown reduced systolic antegrade flow, early systolic retrograde flow, and steep diastolic deceleration in no-reflow arteries. These hemodynamic changes are likely due to microvascular obstruction, myocardial edema, and increased resistance in the coronary microcirculation. The administration of vasodilators, such as nicorandil, directly into the distal coronary artery can effectively reduce microvascular resistance and restore forward blood flow.
The findings of this study have important clinical implications. First, they provide a mechanistic understanding of the no-reflow phenomenon, emphasizing the role of local hemodynamic abnormalities in its pathogenesis. Second, they highlight the therapeutic potential of intracoronary vasodilators, particularly when administered distally through an aspiration catheter. This approach ensures that the drug reaches the microvascular bed, where it can exert its vasodilatory effects and improve coronary flow. Finally, the study underscores the importance of early and effective reperfusion strategies in AMI patients to minimize the risk of no-reflow and its associated complications.
The study also addressed several limitations. First, it was a single-center study with a relatively small sample size, which may limit the generalizability of the findings. Second, the pressure measurements were performed using an aspiration catheter, which, while practical, may not provide the same level of precision as Doppler guidewire measurements. Third, the study did not differentiate between the various causes of no-reflow, such as microvascular obstruction, myocardial edema, or cardiac insufficiency. Future studies with larger sample sizes and more advanced diagnostic tools are needed to further elucidate the mechanisms of no-reflow and optimize treatment strategies.
In conclusion, this study provides valuable insights into the hemodynamic changes associated with the no-reflow phenomenon in AMI patients undergoing pPCI. The inverse intracoronary pressure gradient observed in no-reflow arteries highlights the importance of local hemodynamic abnormalities in its pathogenesis. The administration of nicorandil directly into the distal coronary artery can restore normal pressure gradients and improve microcirculatory function, offering a promising therapeutic approach for managing no-reflow. These findings underscore the need for further research to optimize reperfusion strategies and improve outcomes in AMI patients.
doi.org/10.1097/CM9.0000000000000709
Was this helpful?
0 / 0